Scholarlink

<p>Diabetic macular edema (DME) is one of the leading causes of visual disability among patients with diabetes, affecting nearly 29 million individuals globally. While anti-VEGF therapies have transformed treatment, the burden of frequent intravitreal injections limits long-term adherence and effectiveness. Susvimo (a port delivery system with ranibizumab), recently approved by the U.S. FDA, offers sustained intraocular delivery of anti-VEGF therapy and potentially overcomes major limitations of conventional regimens. This review summarizes the clinical rationale, therapeutic mechanism, patient-centered outcomes, safety profile, and future directions for Susvimo in DME management. Data from pivotal trials such as LADDER and ARCHWAY support its non-inferiority to monthly injections with significant reductions in treatment frequency. While surgical implantation poses specific risks, Susvimo represents a promising shift in managing retinal vascular disorders. This review aims to provide an updated overview of Susvimo’s role in the management of DME, discussing its pharmacological rationale, clinical efficacy, safety, and future perspectives.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Revolutionizing Diabetic Macular Edema Treatment: FDA Approval of Susvimo

  • 期刊论文

  • 发表日期：

    2025年7月21日

查看全文
  • Dinesh Kumar,
  • Vrinda Gupta,
  • Rajni Tanwar,
  • Nicky Kumar Jaiswal

摘要

Diabetic macular edema (DME) is one of the leading causes of visual disability among patients with diabetes, affecting nearly 29 million individuals globally. While anti-VEGF therapies have transformed treatment, the burden of frequent intravitreal injections limits long-term adherence and effectiveness. Susvimo (a port delivery system with ranibizumab), recently approved by the U.S. FDA, offers sustained intraocular delivery of anti-VEGF therapy and potentially overcomes major limitations of conventional regimens. This review summarizes the clinical rationale, therapeutic mechanism, patient-centered outcomes, safety profile, and future directions for Susvimo in DME management. Data from pivotal trials such as LADDER and ARCHWAY support its non-inferiority to monthly injections with significant reductions in treatment frequency. While surgical implantation poses specific risks, Susvimo represents a promising shift in managing retinal vascular disorders. This review aims to provide an updated overview of Susvimo’s role in the management of DME, discussing its pharmacological rationale, clinical efficacy, safety, and future perspectives.